Cargando…

Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study

BACKGROUND: Persistent hypotension is a frequent complication after cardiac surgery with cardiopulmonary bypass (CPB). Midodrine, an orally administered alpha agonist, could potentially reduce intravenous vasopressor use and accelerate ICU discharge of otherwise stable patients. The main objective o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Jan-Alexis, Laramée, Philippe, Lamarche, Yoan, Denault, André, Beaubien-Souligny, William, Frenette, Anne-Julie, Kontar, Loay, Serri, Karim, Charbonney, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490305/
https://www.ncbi.nlm.nih.gov/pubmed/32926256
http://dx.doi.org/10.1186/s13613-020-00737-w
_version_ 1783582013232513024
author Tremblay, Jan-Alexis
Laramée, Philippe
Lamarche, Yoan
Denault, André
Beaubien-Souligny, William
Frenette, Anne-Julie
Kontar, Loay
Serri, Karim
Charbonney, Emmanuel
author_facet Tremblay, Jan-Alexis
Laramée, Philippe
Lamarche, Yoan
Denault, André
Beaubien-Souligny, William
Frenette, Anne-Julie
Kontar, Loay
Serri, Karim
Charbonney, Emmanuel
author_sort Tremblay, Jan-Alexis
collection PubMed
description BACKGROUND: Persistent hypotension is a frequent complication after cardiac surgery with cardiopulmonary bypass (CPB). Midodrine, an orally administered alpha agonist, could potentially reduce intravenous vasopressor use and accelerate ICU discharge of otherwise stable patients. The main objective of this study was to explore the clinical impacts of administering midodrine in patients with persistent hypotension after CPB. Our hypothesis was that midodrine would safely accelerate ICU discharge and be associated with more days free from ICU at 30 days. RESULTS: We performed a retrospective cohort study that included all consecutive patients having received midodrine while being on vasopressor support in the ICU within the first week after cardiac surgery with CPB, between January 2014 and January 2018 at the Montreal Heart Institute. A contemporary propensity score matched control group that included patients who presented similarly prolonged hypotension after cardiac surgery was formed. After matching, 74 pairs of patients (1:1) fulfilled inclusion criteria for the study and control groups. Midodrine use was associated with fewer days free from ICU (25.8 [23.7–27.1] vs 27.2 [25.9–28] days, p = 0.002), higher mortality (10 (13.5%) vs 1 (1.4%), p = 0.036) and longer ICU length of stay (99 [68–146] vs 68 [48–99] hours, p = 0.001). There was no difference in length of intravenous vasopressors (63 [40–87] vs 44 [26–66] hours, p = 0.052), rate of ICU readmission (6 (8.1%) vs 2 (2.7%), p = 0.092) and occurrence of severe kidney injury (11 (14.9%) vs 10 (13.5%) patients, p = 0.462) between groups. CONCLUSION: The administration of midodrine for sustained hypotension after cardiac surgery with CPB was associated with fewer days free from ICU and higher mortality. Routine prescription of midodrine to hasten ICU discharge after cardiac surgery should be used with caution until further prospective studies are conducted.
format Online
Article
Text
id pubmed-7490305
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74903052020-09-24 Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study Tremblay, Jan-Alexis Laramée, Philippe Lamarche, Yoan Denault, André Beaubien-Souligny, William Frenette, Anne-Julie Kontar, Loay Serri, Karim Charbonney, Emmanuel Ann Intensive Care Research BACKGROUND: Persistent hypotension is a frequent complication after cardiac surgery with cardiopulmonary bypass (CPB). Midodrine, an orally administered alpha agonist, could potentially reduce intravenous vasopressor use and accelerate ICU discharge of otherwise stable patients. The main objective of this study was to explore the clinical impacts of administering midodrine in patients with persistent hypotension after CPB. Our hypothesis was that midodrine would safely accelerate ICU discharge and be associated with more days free from ICU at 30 days. RESULTS: We performed a retrospective cohort study that included all consecutive patients having received midodrine while being on vasopressor support in the ICU within the first week after cardiac surgery with CPB, between January 2014 and January 2018 at the Montreal Heart Institute. A contemporary propensity score matched control group that included patients who presented similarly prolonged hypotension after cardiac surgery was formed. After matching, 74 pairs of patients (1:1) fulfilled inclusion criteria for the study and control groups. Midodrine use was associated with fewer days free from ICU (25.8 [23.7–27.1] vs 27.2 [25.9–28] days, p = 0.002), higher mortality (10 (13.5%) vs 1 (1.4%), p = 0.036) and longer ICU length of stay (99 [68–146] vs 68 [48–99] hours, p = 0.001). There was no difference in length of intravenous vasopressors (63 [40–87] vs 44 [26–66] hours, p = 0.052), rate of ICU readmission (6 (8.1%) vs 2 (2.7%), p = 0.092) and occurrence of severe kidney injury (11 (14.9%) vs 10 (13.5%) patients, p = 0.462) between groups. CONCLUSION: The administration of midodrine for sustained hypotension after cardiac surgery with CPB was associated with fewer days free from ICU and higher mortality. Routine prescription of midodrine to hasten ICU discharge after cardiac surgery should be used with caution until further prospective studies are conducted. Springer International Publishing 2020-09-14 /pmc/articles/PMC7490305/ /pubmed/32926256 http://dx.doi.org/10.1186/s13613-020-00737-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Tremblay, Jan-Alexis
Laramée, Philippe
Lamarche, Yoan
Denault, André
Beaubien-Souligny, William
Frenette, Anne-Julie
Kontar, Loay
Serri, Karim
Charbonney, Emmanuel
Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
title Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
title_full Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
title_fullStr Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
title_full_unstemmed Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
title_short Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
title_sort potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490305/
https://www.ncbi.nlm.nih.gov/pubmed/32926256
http://dx.doi.org/10.1186/s13613-020-00737-w
work_keys_str_mv AT tremblayjanalexis potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT larameephilippe potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT lamarcheyoan potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT denaultandre potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT beaubiensoulignywilliam potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT frenetteannejulie potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT kontarloay potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT serrikarim potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy
AT charbonneyemmanuel potentialrisksinusingmidodrineforpersistenthypotensionaftercardiacsurgeryacomparativecohortstudy